Is ICCM or ECOR more profitable?

electroCore has a net margin of -44.08% compared to IceCure Medical's net margin of -441.60%. IceCure Medical's return on equity of -211.73% beat electroCore's return on equity. Company Net Margins Return on Equity Return on Assets IceCure Medical -441.60% -211.73% -119.13% electroCore -44.08% -1,956.38% -83.30%

Does the media refer more to ICCM or ECOR?

In the previous week, electroCore had 4 more articles in the media than IceCure Medical. MarketBeat recorded 7 mentions for electroCore and 3 mentions for IceCure Medical. IceCure Medical's average media sentiment score of 0.88 beat electroCore's score of 0.70 indicating that IceCure Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IceCure Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive electroCore 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LNSR or ICCM more profitable?

LENSAR has a net margin of 50.94% compared to IceCure Medical's net margin of -441.60%. LENSAR's return on equity of -183.19% beat IceCure Medical's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 50.94% -183.19% 42.26% IceCure Medical -441.60% -211.73% -119.13%

Do analysts recommend ICCM or AGPU?

IceCure Medical currently has a consensus price target of $2.09, indicating a potential upside of 960.91%. Given IceCure Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe IceCure Medical is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IceCure Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ICCM or AGPU?

In the previous week, IceCure Medical and IceCure Medical both had 3 articles in the media. IceCure Medical's average media sentiment score of 0.88 beat Predictive Oncology's score of 0.51 indicating that IceCure Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IceCure Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Predictive Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BDMD or ICCM?

IceCure Medical has a consensus price target of $2.09, suggesting a potential upside of 960.91%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts plainly believe IceCure Medical is more favorable than Baird Medical Investment. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Baird Medical Investment 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IceCure Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has higher valuation and earnings, BDMD or ICCM?

Baird Medical Investment has higher revenue and earnings than IceCure Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Baird Medical Investment $22.54M 2.63 N/A N/A N/A IceCure Medical $3.38M 4.73 -$15.06M -$0.24 N/A

Is LUNG or ICCM more profitable?

Pulmonx has a net margin of -60.09% compared to IceCure Medical's net margin of -441.60%. Pulmonx's return on equity of -92.94% beat IceCure Medical's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -60.09% -92.94% -39.80% IceCure Medical -441.60% -211.73% -119.13%

IceCure Medical (ICCM) Competitors

$0.20 -0.02 (-10.05%)

As of 03:09 PM Eastern

Compare

ICCM vs. ECOR, LNSR, AGPU, BDMD, and LUNG

Should you buy IceCure Medical stock or one of its competitors? MarketBeat compares IceCure Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IceCure Medical include electroCore (ECOR), LENSAR (LNSR), Predictive Oncology (AGPU), Baird Medical Investment (BDMD), and Pulmonx (LUNG). These companies are all part of the "medical equipment" industry.

How does IceCure Medical compare to electroCore?

IceCure Medical (NASDAQ:ICCM) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

electroCore has a net margin of -44.08% compared to IceCure Medical's net margin of -441.60%. IceCure Medical's return on equity of -211.73% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-441.60%	-211.73%	-119.13%
electroCore	-44.08%	-1,956.38%	-83.30%

IceCure Medical has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, electroCore has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 26.7% of electroCore shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by insiders. Comparatively, 13.8% of electroCore shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

electroCore has higher revenue and earnings than IceCure Medical. electroCore is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38M	4.73	-$15.06M	-$0.24	N/A
electroCore	$32.03M	2.63	-$13.97M	-$1.77	N/A

In the previous week, electroCore had 4 more articles in the media than IceCure Medical. MarketBeat recorded 7 mentions for electroCore and 3 mentions for IceCure Medical. IceCure Medical's average media sentiment score of 0.88 beat electroCore's score of 0.70 indicating that IceCure Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IceCure Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
electroCore	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IceCure Medical presently has a consensus target price of $2.09, suggesting a potential upside of 960.91%. electroCore has a consensus target price of $18.00, suggesting a potential upside of 77.39%. Given IceCure Medical's stronger consensus rating and higher possible upside, equities research analysts plainly believe IceCure Medical is more favorable than electroCore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

IceCure Medical and electroCore tied by winning 8 of the 16 factors compared between the two stocks.

How does IceCure Medical compare to LENSAR?

LENSAR (NASDAQ:LNSR) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

40.2% of LENSAR shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 66.0% of LENSAR shares are held by company insiders. Comparatively, 2.4% of IceCure Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

LENSAR has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

LENSAR has a net margin of 50.94% compared to IceCure Medical's net margin of -441.60%. LENSAR's return on equity of -183.19% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	50.94%	-183.19%	42.26%
IceCure Medical	-441.60%	-211.73%	-119.13%

IceCure Medical has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.18	-$34.28M	-$0.58	N/A
IceCure Medical	$3.38M	4.73	-$15.06M	-$0.24	N/A

In the previous week, IceCure Medical had 2 more articles in the media than LENSAR. MarketBeat recorded 3 mentions for IceCure Medical and 1 mentions for LENSAR. LENSAR's average media sentiment score of 1.87 beat IceCure Medical's score of 0.88 indicating that LENSAR is being referred to more favorably in the media.

Company	Overall Sentiment
LENSAR	Very Positive
IceCure Medical	Positive

LENSAR presently has a consensus price target of $10.00, suggesting a potential upside of 75.44%. IceCure Medical has a consensus price target of $2.09, suggesting a potential upside of 960.91%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts plainly believe IceCure Medical is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

LENSAR and IceCure Medical tied by winning 8 of the 16 factors compared between the two stocks.

How does IceCure Medical compare to Predictive Oncology?

IceCure Medical (NASDAQ:ICCM) and Predictive Oncology (NASDAQ:AGPU) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

IceCure Medical has a net margin of -441.60% compared to Predictive Oncology's net margin of -470,383.31%. IceCure Medical's return on equity of -211.73% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-441.60%	-211.73%	-119.13%
Predictive Oncology	-470,383.31%	-7,363.67%	-626.32%

IceCure Medical currently has a consensus price target of $2.09, indicating a potential upside of 960.91%. Given IceCure Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe IceCure Medical is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, IceCure Medical and IceCure Medical both had 3 articles in the media. IceCure Medical's average media sentiment score of 0.88 beat Predictive Oncology's score of 0.51 indicating that IceCure Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IceCure Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Predictive Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

IceCure Medical has higher revenue and earnings than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38M	4.73	-$15.06M	-$0.24	N/A
Predictive Oncology	$120K	647.83	-$233.10M	-$8.18	N/A

IceCure Medical has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 3.47, indicating that its stock price is 247% more volatile than the broader market.

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

IceCure Medical beats Predictive Oncology on 12 of the 15 factors compared between the two stocks.

How does IceCure Medical compare to Baird Medical Investment?

Baird Medical Investment (NASDAQ:BDMD) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Baird Medical Investment has a net margin of 0.00% compared to IceCure Medical's net margin of -441.60%. Baird Medical Investment's return on equity of 0.00% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baird Medical Investment	N/A	N/A	N/A
IceCure Medical	-441.60%	-211.73%	-119.13%

IceCure Medical has a consensus price target of $2.09, suggesting a potential upside of 960.91%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts plainly believe IceCure Medical is more favorable than Baird Medical Investment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baird Medical Investment	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by company insiders. Comparatively, 2.4% of IceCure Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, IceCure Medical had 1 more articles in the media than Baird Medical Investment. MarketBeat recorded 3 mentions for IceCure Medical and 2 mentions for Baird Medical Investment. Baird Medical Investment's average media sentiment score of 1.43 beat IceCure Medical's score of 0.88 indicating that Baird Medical Investment is being referred to more favorably in the media.

Company	Overall Sentiment
Baird Medical Investment	Positive
IceCure Medical	Positive

Baird Medical Investment has higher revenue and earnings than IceCure Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baird Medical Investment	$22.54M	2.63	N/A	N/A	N/A
IceCure Medical	$3.38M	4.73	-$15.06M	-$0.24	N/A

Baird Medical Investment has a beta of -1.22, indicating that its stock price is 222% less volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Summary

Baird Medical Investment beats IceCure Medical on 7 of the 13 factors compared between the two stocks.

How does IceCure Medical compare to Pulmonx?

Pulmonx (NASDAQ:LUNG) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Pulmonx has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Pulmonx has a net margin of -60.09% compared to IceCure Medical's net margin of -441.60%. Pulmonx's return on equity of -92.94% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
IceCure Medical	-441.60%	-211.73%	-119.13%

In the previous week, IceCure Medical had 2 more articles in the media than Pulmonx. MarketBeat recorded 3 mentions for IceCure Medical and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.89 beat IceCure Medical's score of 0.88 indicating that Pulmonx is being referred to more favorably in the media.

Company	Overall Sentiment
Pulmonx	Very Positive
IceCure Medical	Positive

IceCure Medical has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.76	-$54M	-$1.30	N/A
IceCure Medical	$3.38M	4.73	-$15.06M	-$0.24	N/A

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 6.8% of Pulmonx shares are held by insiders. Comparatively, 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Pulmonx currently has a consensus target price of $5.58, indicating a potential upside of 244.65%. IceCure Medical has a consensus target price of $2.09, indicating a potential upside of 960.91%. Given IceCure Medical's higher possible upside, analysts plainly believe IceCure Medical is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Pulmonx beats IceCure Medical on 9 of the 16 factors compared between the two stocks.

Get IceCure Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ICCM vs. The Competition

Export

Metric	IceCure Medical	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.00M	$8.50B	$6.32B	$12.64B
Dividend Yield	N/A	1.76%	2.68%	5.31%
P/E Ratio	-0.82	21.75	21.14	26.75
Price / Sales	4.73	19.34	548.19	115.38
Price / Cash	N/A	12.89	27.44	37.60
Price / Book	1.64	5.08	9.92	6.92
Net Income	-$15.06M	$175.77M	$3.56B	$336.84M
7 Day Performance	-16.17%	2.29%	2.24%	4.33%
1 Month Performance	N/A	N/A	N/A	-0.37%
1 Year Performance	-81.24%	5.55%	36.82%	40.73%

IceCure Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ICCM IceCure Medical	2.65 of 5 stars	$0.20 -10.0%	$2.09 +960.9%	-79.1%	$16.00M	$3.38M	N/A	60	High Trading Volume
ECOR electroCore	3.2297 of 5 stars	$8.85 +32.7%	$18.00 +103.4%	+92.1%	$73.46M	$32.03M	N/A	50	Gap Up High Trading Volume
LNSR LENSAR	2.3573 of 5 stars	$5.95 -2.3%	$10.00 +68.1%	-57.3%	$72.00M	$58.44M	N/A	110	Positive News
AGPU Predictive Oncology	0.4374 of 5 stars	$6.85 +28.3%	N/A	N/A	$71.24M	$120K	N/A	30	Analyst Downgrade Gap Down
BDMD Baird Medical Investment	1.4959 of 5 stars	$1.61 -1.2%	N/A	-58.3%	$65.98M	$22.54M	N/A	N/A	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ICCM) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IceCure Medical (ICCM) Competitors

ICCM vs. ECOR, LNSR, AGPU, BDMD, and LUNG

How does IceCure Medical compare to electroCore?

Summary

How does IceCure Medical compare to LENSAR?

Summary

How does IceCure Medical compare to Predictive Oncology?

Summary

How does IceCure Medical compare to Baird Medical Investment?

Summary

How does IceCure Medical compare to Pulmonx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCM vs. The Competition

IceCure Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IceCure Medical (ICCM) Competitors

ICCM vs. ECOR, LNSR, AGPU, BDMD, and LUNG

How does IceCure Medical compare to electroCore?

Is ICCM or ECOR more profitable?

Which has more volatility and risk, ICCM or ECOR?

Do institutionals & insiders hold more shares of ICCM or ECOR?

Which has better valuation and earnings, ICCM or ECOR?

Does the media refer more to ICCM or ECOR?

Do analysts prefer ICCM or ECOR?

Summary

How does IceCure Medical compare to LENSAR?

Do insiders & institutionals have more ownership in LNSR or ICCM?

Which has more volatility and risk, LNSR or ICCM?

Is LNSR or ICCM more profitable?

Which has higher valuation & earnings, LNSR or ICCM?

Does the media refer more to LNSR or ICCM?

Do analysts rate LNSR or ICCM?

Summary

How does IceCure Medical compare to Predictive Oncology?

Is ICCM or AGPU more profitable?

Do analysts recommend ICCM or AGPU?

Does the media favor ICCM or AGPU?

Which has higher valuation and earnings, ICCM or AGPU?

Which has more volatility and risk, ICCM or AGPU?

Do insiders & institutionals have more ownership in ICCM or AGPU?

Summary

How does IceCure Medical compare to Baird Medical Investment?

Is BDMD or ICCM more profitable?

Do analysts rate BDMD or ICCM?

Do institutionals & insiders have more ownership in BDMD or ICCM?

Does the media refer more to BDMD or ICCM?

Which has higher valuation and earnings, BDMD or ICCM?

Which has more volatility and risk, BDMD or ICCM?

Summary

How does IceCure Medical compare to Pulmonx?

Which has more volatility and risk, LUNG or ICCM?

Is LUNG or ICCM more profitable?

Does the media refer more to LUNG or ICCM?

Which has higher earnings & valuation, LUNG or ICCM?

Do insiders and institutionals believe in LUNG or ICCM?

Do analysts prefer LUNG or ICCM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCM vs. The Competition

IceCure Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools